Why J&J Thinks Its New Psoriasis Pill Could Be One of Its Biggest Drugs Ever

Why It Matters

Icotyde could revitalize J&J’s immunology franchise and offset declining Stelara revenues, while offering patients a convenient oral alternative to biologics.

Key Takeaways

• Icotyde received FDA approval in March 2026 for moderate‑to‑severe plaque psoriasis
• First oral IL‑23 inhibitor, competing directly with injectable biologics
• ~1,500 prescriptions written in the first month of launch
• Analysts forecast $10.5 billion sales by 2032 if payer access succeeds
• J&J aims to expand Icotyde into Crohn’s disease and ulcerative colitis

Pulse Analysis

The psoriasis treatment landscape has been dominated by injectable biologics that target the IL‑23 pathway, such as J&J’s Tremfya and AbbVie’s Skyrizi. While these agents have driven billions in revenue, they require quarterly or monthly injections, limiting adherence for some patients. Icotyde’s entry as the first oral IL‑23 inhibitor addresses a long‑standing demand for a convenient, once‑daily tablet, potentially reshaping prescribing habits and expanding the addressable market beyond the roughly 8 million U.S. patients with plaque psoriasis.

Early market signals suggest Icotyde is gaining traction. Within 30 days of its launch, physicians wrote about 1,500 prescriptions, a modest but promising start for a novel modality. Analysts at Leerink have raised their sales target to $10.5 billion for 2032, reflecting confidence that broader payer coverage and additional label expansions—particularly into inflammatory bowel disease—could unlock substantial upside. By contrast, Bristol‑Myers‑Squibb’s oral TYK2 inhibitor Sotyktu struggled to gain market share, underscoring the importance of reimbursement pathways and physician acceptance for pill‑based therapies.

For Johnson & Johnson, Icotyde represents a strategic hedge against the erosion of Stelara’s earnings after its 2023 patent expiry. Tremfya’s sales are projected to reach $7.13 billion in 2026, but the company seeks a “category‑shaping” portfolio that captures patients who prefer oral treatment. If Icotyde secures approvals for Crohn’s disease and ulcerative colitis, it could tap the same IBD revenue stream that accounted for 75% of Stelara’s sales, reinforcing J&J’s goal of double‑digit growth by decade’s end. The drug’s performance will be a bellwether for how quickly the pharma industry can shift entrenched biologic markets toward oral alternatives.